[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adc Therapeutics Sa (ADCT)

Adc Therapeutics Sa (ADCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 403,195
  • Shares Outstanding, K 127,191
  • Annual Sales, $ 81,360 K
  • Annual Income, $ -142,620 K
  • EBIT $ -118 M
  • EBITDA $ -116 M
  • 60-Month Beta 1.83
  • Price/Sales 5.08
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 444.51% (+242.87%)
  • Historical Volatility 51.85%
  • IV Percentile 78%
  • IV Rank 50.94%
  • IV High 832.28% on 02/11/26
  • IV Low 41.82% on 02/18/26
  • Expected Move (DTE 30) 1.46 (46.56%)
  • Put/Call Vol Ratio 2.11
  • Today's Volume 59
  • Volume Avg (30-Day) 101
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 3,612
  • Open Int (30-Day) 3,159
  • Expected Range 1.68 to 4.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.19
  • Number of Estimates 1
  • High Estimate $-0.19
  • Low Estimate $-0.19
  • Prior Year $-0.50
  • Growth Rate Est. (year over year) +62.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.10 +1.29%
on 05/19/26
4.33 -27.48%
on 04/20/26
-1.14 (-26.64%)
since 04/17/26
3-Month
3.10 +1.29%
on 05/19/26
4.98 -36.95%
on 03/11/26
-1.08 (-25.59%)
since 02/19/26
52-Week
1.83 +71.58%
on 05/22/25
4.98 -36.95%
on 03/11/26
+0.80 (+34.19%)
since 05/19/25

Most Recent Stories

More News
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end

ADCT : 3.14 (-0.95%)
ADC Therapeutics Reports Monday With Single-Product Dependency and No Clear Path to Profitability

Barchart Research What to Expect from ADCT Earnings ADCT Generated May 1, 2026 Current Price $3.83 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 10.96% ADC Therapeutics Reports Monday With...

ADCT : 3.14 (-0.95%)
ADC Therapeutics Reports Monday With Single-Product Dependency and No Clear Path to Profitability

Barchart Research What to Expect from ADCT Earnings ADCT Generated May 1, 2026 Current Price $3.83 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 10.96% ADC Therapeutics Reports Monday With...

ADCT : 3.14 (-0.95%)
ADC Therapeutics Reports Monday With Single-Product Dependency and No Clear Path to Profitability

Barchart Research What to Expect from ADCT Earnings ADCT Generated May 1, 2026 Current Price $3.83 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 10.96% ADC Therapeutics Reports Monday With...

ADCT : 3.14 (-0.95%)
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland , May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...

ADCT : 3.14 (-0.95%)
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

LAUSANNE, Switzerland , April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...

ADCT : 3.14 (-0.95%)
ADC Therapeutics Announces New Employee Inducement Grant

LAUSANNE, Switzerland , April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...

ADCT : 3.14 (-0.95%)
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026

ADCT : 3.14 (-0.95%)
ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026

LAUSANNE, Switzerland , March 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...

ADCT : 3.14 (-0.95%)
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland , March 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...

ADCT : 3.14 (-0.95%)

Business Summary

ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.

See More

Key Turning Points

3rd Resistance Point 3.34
2nd Resistance Point 3.29
1st Resistance Point 3.21
Last Price 3.14
1st Support Level 3.08
2nd Support Level 3.03
3rd Support Level 2.95

See More

52-Week High 4.98
Fibonacci 61.8% 3.78
Fibonacci 50% 3.40
Last Price 3.14
Fibonacci 38.2% 3.03
52-Week Low 1.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.